113 related articles for article (PubMed ID: 24882036)
1. In vitro and in vivo evaluation of chitosan graft glyceryl monooleate as peroral delivery carrier of enoxaparin.
Wang L; Li L; Sun Y; Ding J; Li J; Duan X; Li Y; Junyaprasert VB; Mao S
Int J Pharm; 2014 Aug; 471(1-2):391-9. PubMed ID: 24882036
[TBL] [Abstract][Full Text] [Related]
2. Uptake, transport and peroral absorption of fatty glyceride grafted chitosan copolymer-enoxaparin nanocomplexes: influence of glyceride chain length.
Wang L; Sun Y; Shi C; Li L; Guan J; Zhang X; Ni R; Duan X; Li Y; Mao S
Acta Biomater; 2014 Aug; 10(8):3675-85. PubMed ID: 24814881
[TBL] [Abstract][Full Text] [Related]
3. Exploration of hydrophobic modification degree of chitosan-based nanocomplexes on the oral delivery of enoxaparin.
Wang L; Li L; Sun Y; Tian Y; Li Y; Li C; Junyaprasert VB; Mao S
Eur J Pharm Sci; 2013 Nov; 50(3-4):263-71. PubMed ID: 23896170
[TBL] [Abstract][Full Text] [Related]
4. Chitosan based polymer-lipid hybrid nanoparticles for oral delivery of enoxaparin.
Dong W; Wang X; Liu C; Zhang X; Zhang X; Chen X; Kou Y; Mao S
Int J Pharm; 2018 Aug; 547(1-2):499-505. PubMed ID: 29859924
[TBL] [Abstract][Full Text] [Related]
5. Bioadhesion and oral absorption of enoxaparin nanocomplexes.
Sun W; Mao S; Wang Y; Junyaprasert VB; Zhang T; Na L; Wang J
Int J Pharm; 2010 Feb; 386(1-2):275-81. PubMed ID: 19958824
[TBL] [Abstract][Full Text] [Related]
6. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
7. Uptake and transport of PEG-graft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells.
Mao S; Germershaus O; Fischer D; Linn T; Schnepf R; Kissel T
Pharm Res; 2005 Dec; 22(12):2058-68. PubMed ID: 16170693
[TBL] [Abstract][Full Text] [Related]
8. Enhanced oral insulin delivery via surface hydrophilic modification of chitosan copolymer based self-assembly polyelectrolyte nanocomplex.
Liu C; Kou Y; Zhang X; Dong W; Cheng H; Mao S
Int J Pharm; 2019 Jan; 554():36-47. PubMed ID: 30385377
[TBL] [Abstract][Full Text] [Related]
9. Polysaccharides-based nanocomplexes for the prolonged delivery of enoxaparin: In-vitro and in-vivo evaluation.
Ibrahim SS; Osman R; Awad GAS; Mortada ND; Geneidi AS
Int J Pharm; 2017 Jun; 526(1-2):271-279. PubMed ID: 28479519
[TBL] [Abstract][Full Text] [Related]
10. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
[TBL] [Abstract][Full Text] [Related]
11. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin.
Sun W; Mao S; Mei D; Kissel T
Eur J Pharm Biopharm; 2008 Jun; 69(2):417-25. PubMed ID: 18294825
[TBL] [Abstract][Full Text] [Related]
12. Mucoadhesive hydrogel microparticles based on poly (methacrylic acid-vinyl pyrrolidone)-chitosan for oral drug delivery.
Sajeesh S; Sharma CP
Drug Deliv; 2011 May; 18(4):227-35. PubMed ID: 21067275
[TBL] [Abstract][Full Text] [Related]
13. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery.
Yin L; Ding J; He C; Cui L; Tang C; Yin C
Biomaterials; 2009 Oct; 30(29):5691-700. PubMed ID: 19615735
[TBL] [Abstract][Full Text] [Related]
14. Thermoreversible in situ gelling poloxamer-based systems with chitosan nanocomplexes for prolonged subcutaneous delivery of heparin: design and in vitro evaluation.
Radivojša M; Grabnar I; Ahlin Grabnar P
Eur J Pharm Sci; 2013 Sep; 50(1):93-101. PubMed ID: 23524253
[TBL] [Abstract][Full Text] [Related]
15. Topical delivery of enoxaparin using nanostructured lipid carrier.
Jain A; Mehra NK; Nahar M; Jain NK
J Microencapsul; 2013; 30(7):709-15. PubMed ID: 23534492
[TBL] [Abstract][Full Text] [Related]
16. N-octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: preparation, characterization and its study on in situ intestinal perfusion.
Yu F; He C; Waddad AY; Munyendo WL; Lv H; Zhou J; Zhang Q
Drug Dev Ind Pharm; 2014 Jun; 40(6):774-82. PubMed ID: 23679668
[TBL] [Abstract][Full Text] [Related]
17. The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery.
Millotti G; Perera G; Vigl C; Pickl K; Sinner FM; Bernkop-Schnürch A
Drug Deliv; 2011 Apr; 18(3):190-7. PubMed ID: 21039318
[TBL] [Abstract][Full Text] [Related]
18. Complexation of a poly-L-arginine with low molecular weight heparin enhances pulmonary absorption of the drug.
Rawat A; Yang T; Hussain A; Ahsan F
Pharm Res; 2008 Apr; 25(4):936-48. PubMed ID: 17955186
[TBL] [Abstract][Full Text] [Related]
19. Effect of high-pressure homogenization and stabilizers on the physicochemical properties of curcumin-loaded glycerol monooleate/chitosan nanostructures.
Mistry PH; Mohapatra SK; Dash AK
Nanomedicine (Lond); 2012 Dec; 7(12):1863-76. PubMed ID: 22709346
[TBL] [Abstract][Full Text] [Related]
20. Surface modification of nanostructure lipid carrier (NLC) by oleoyl-quaternized-chitosan as a mucoadhesive nanocarrier.
Yostawonkul J; Surassmo S; Iempridee T; Pimtong W; Suktham K; Sajomsang W; Gonil P; Ruktanonchai UR
Colloids Surf B Biointerfaces; 2017 Jan; 149():301-311. PubMed ID: 27780087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
